When will this data be made public?
Albert Burla, chief executive of Pfizer, said several times recently that the company expected that ‘final’ efficacy data would arrive by October. On September 26, 60 US scientists and health experts wrote to Pfizer not to send the vaccine for regulatory clearance until the vaccine meets all safety standards.
Why is this data being viewed from suspicious cities?
The data that has emerged regarding the effect of vaccine is being closely monitored. Especially given the election of the American President. Significantly, President Donald Trump has repeatedly said that a vaccine will be approved before the vote on 3 November. Pfizer’s data is also being challenged because it placed a limit of very few infections in the trial. According to an Airfinity analyst, Pfizer’s choice of 32 events is the lowest ever and has been criticized everywhere. According to the company, four interim analyzes in a phase-3 trial have not occurred in any vaccine trial before.
How long is the approval expected?
America’s Food and Drug Administration (FDA) will decide on the vaccine. It has a meeting on October 22 to discuss possible Kovid-19 vaccines.
Which vaccines are the eye of the world?
Apart from Pfizer, there are many vaccines in the world, whose development is closely watched. These include Oxford-AstraZeneca’s adenovirus vector single dose vaccine, Moderna’s mRNA double dose vaccine, Sinovac’s inactivated double dose vaccine.